[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
February 2015

Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Author Affiliations
  • 1Department of Neurology, University of Utah, Salt Lake City
  • 2Department of Neurology, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2015;72(2):147-149. doi:10.1001/jamaneurol.2014.3831

Stem cell transplant for multiple sclerosis (MS) has been a subject of great interest to scientists, physicians, and patients. The status of stem cell therapy is a common question posed by patients at their annual MS visit, usually as a parting query. Most patients have a vague concept of stem cell therapy, typically one that has been molded by a perception that stem cell therapy is regenerative. Therapies that promote regeneration of lost myelin and axons are all but absent from the current armamentarium of neurologists.